

Date: August 06, 2024

Ref. No.: KDL/SE/053/2024-25

To, BSE Limited Corporate Relationship Department 25th Floor, Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 543328	To, National Stock Exchange of India Limited Exchange Plaza, Plot No. C-1, Block G, Bandra Kurla Complex, Bandra (East) Mumbai – 400051 NSE Symbol: KRSNAA
--	--

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Investor Presentation.

Pursuant to the Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a copy of the presentation for the Investors/Analysts on Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2024.

Request you to take the same on your records.

Thanking you,
Yours sincerely,

For **Krsnaa Diagnostics Limited**



Sujoy Sudipta Bose
Company Secretary & Compliance Officer
Encl: as above



Q1FY2025 Result Presentation

One of INDIA'S LARGEST Differentiated Diagnostic Service Provider



Q1FY2025 Performance

Krsnaa Diagnostics Q1FY25 – Operations at a Glance



Bharat ka Bharosemand Diagnostics

India's 1st
CAP Accreditation
in Govt. Hospital

India's 1st
NABH Accredited Tele
radiology HUB

Radiology

168
CT/MRI Centres

1,443
Tele-Reporting
Centre

Pathology

120
Processing lab

2,270
Collection
Centre

NABH
22
Accredited
centres

NABL
23
Accredited
centres



Presence In India

150+
District Location

17
States & Union
Territories

Patient served

40Mn+
Last 3 years

Doctors Associated

500+

Strengths

~ 1.5 Lakh
CT & MRI Scans per
month

~ 6 lakhs
X-rays per month

CAGR

24%
Last 5 years

ICRA Rating

A
Stable

Bid Win Ratio



75%+

Krsnaa Diagnostics Q1FY25 – Financials at a Glance



In mn

Maintaining Growth Momentum: Achieving 22% YoY Revenue Growth, 39% YoY EBITDA Strengthening & 22% YoY improvement in PAT, on account of network expansion and enhanced operational efficiency



Note: EBIDTA & EBIDTA Margin are before CSR & ESOP, Diluted EPS in INR




Q1FY25 EBITDA Analysis



In mn

EBITDA Margins Before CSR and ESOP

Gross Profit Margins



Note: Considering the nature of business, financial performance is best evaluated on an annualized basis.

Financial Performance



In mn

Particulars	Q1 FY 25		Q1 FY 24		Q4 FY 24		FY 24		FY 23	
	Amount	%	Amount	%	Amount	%	Amount	%	Amount	%
Revenue from operations	1,702		1,396		1,663		6,196		4,871	
Expenses										
Cost of Material Consumed	429	25%	278	20%	430	26%	1,410	23%	742	15%
Employee benefits expense	320	19%	228	16%	324	19%	1,106	18%	739	15%
Fees to hospitals and others	123	7%	174	13%	94	6%	655	11%	812	17%
Other expenses	388	23%	398	29%	374	22%	1,560	25%	1,338	27%
Total Expenses	1,261	74%	1,077	77%	1,222	73%	4,731	76%	3,631	75%
EBITDA Before CSR & ESOP	442	26%	319	23%	441	27%	1,465	24%	1240	25%
CSR and ESOP	15	1%	5	0%	4	0%	23	0%	17	0%
EBITDA	427	25%	314	23%	437	26%	1,442	23%	1223	25%
Less: Finance costs	53	3%	20	1%	73	4%	165	3%	77	2%
Less: Depreciation	215	13%	157	11%	181	11%	745	12%	538	11%
Add: Other income	73	4%	42	3%	43	3%	168	3%	194	4%
PBT	232	14%	179	13%	226	14%	700	11%	802	16%
Tax	53	3%	32	2%	39	2%	132	2%	181	4%
PAT	179	11%	146	11%	187	11%	568	9%	621	13%

Note: The PAT for Q4FY24 after adjusting the depreciation benefit of Rs. 397 million due to change in accounting estimates for the entire last year which was accounted for in Q4 FY24, would have been Rs. 158 million, **resulting in PAT growing by 14% in Q1FY25 as compared to Q4FY24 demonstrating a healthy growth**




Operational Highlights

Only Company with Pan India Presence in Both Radiology and Pathology



*Under Implementation
 ** The USG, Dexa, Mammography and TMT Centres are not marked in this map.

Well Diversified Regional Revenue Mix



High Headroom to Grow

- Highest penetration across districts with presence in 150+ out of 700+ districts; still large underpenetrated market
- Government continuous focus on improving healthcare in India and looking to partner under PPP model
- Krsnaa is already present in most of the tier I, II, III and rural areas. Krsnaa plans to leverage its extensive presence for growth



Recent Developments

Project under Implementation



Radiology Centres Under Implementation

	Total Centres	Operational	Under Implementation
Uttar Pradesh	8	5	3
Delhi	1	1	-
DMC	1	-	1
Mira Bhayandar	1	-	1
Rajasthan	1	-	1
Maharashtra	73	32	41
Madhya Pradesh	5	-	5
Total	90	38	52

Pathology Centres Under Implementation

	Total Centres	Operational	Under Implementation
DMC	1	-	1
BMC CC	600	473	127
Odisha CC	600	-	600
Mira Bhayandar	1	-	1
Assam	10	9	1
Assam CC	1,256	387	869
Total	2,468	869	1,599


One of the only company in India to have 220 CT / MRI centers installed & operational / under installation




Way Forward



We aim to sustain the upward trajectory of our Revenue and PAT CAGR by utilizing our existing facilities and seizing opportunities in untapped markets



Note: Our growth strategy is well defined and allows us to achieve steady state growth irrespective of dependence on individual projects like Rajasthan





This presentation contains statements that are “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Krsnaa Diagnostics’ future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations.

These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance.

Krsnaa Diagnostics undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.

For further information please contact:

Krsnaa Diagnostics

Vivek Jain, Investor Relation Head

head.investor@krsnaa.in

Contact: +91 74107 00645